NEWSAR
Multi-perspective news intelligence
SRCThe Guardian - World News
LANGEN
LEANCenter-Left
WORDS563
ENT4
THU · 2026-04-09 · 15:00 GMTBRIEF NSR-2026-0409-60620
News/Woman with three deadly diseases has ‘remarkable’ recovery a…
NSR-2026-0409-60620News Report·EN·Public Health

Woman with three deadly diseases has ‘remarkable’ recovery after cell therapy

A 47-year-old woman in Germany experienced a "remarkable" recovery from three life-threatening autoimmune diseases after receiving cell therapy at University Hospital Erlangen. The woman, who had autoimmune haemolytic anaemia (AIHA), immune thrombocytopenia (ITP), and antiphospholipid syndrome (APS), had been suffering for over a decade and was unresponsive to conventional treatments.

Ian Sample Science editorThe Guardian - World NewsFiled 2026-04-09 · 15:00 GMTLean · Center-LeftRead · 3 min
Woman with three deadly diseases has ‘remarkable’ recovery after cell therapy
The Guardian - World NewsFIG 01
Reading time
3min
Word count
563words
Sources cited
3cited
Entities identified
4entities
Quality score
100%
§ 01

Briefing Summary

AI-generated
NEWSAR · AI

A 47-year-old woman in Germany experienced a "remarkable" recovery from three life-threatening autoimmune diseases after receiving cell therapy at University Hospital Erlangen. The woman, who had autoimmune haemolytic anaemia (AIHA), immune thrombocytopenia (ITP), and antiphospholipid syndrome (APS), had been suffering for over a decade and was unresponsive to conventional treatments. Doctors used CAR T-cell therapy, modifying her T-cells to target and destroy the rogue B-cells causing her conditions. Within weeks of the treatment, all three diseases responded, and she has been in treatment-free remission for 14 months, allowing her to return to a near-normal life. While the results are promising, researchers emphasize the need for clinical trials to determine the therapy's long-term effectiveness and applicability to other autoimmune diseases.

Confidence 0.90Sources 3Claims 5Entities 4
§ 02

Article analysis

Model · rule-based
Framing
Public Health
Technology
Tone
Mixed Tone
AI-assessed
CalmNeutralAlarmist
Factuality
0.80 / 1.00
Factual
LowHigh
Sources cited
3
Well sourced
FewMany
§ 03

Key claims

5 extracted
01

The patient had no treatment options left and would not have left the ward as she needed daily transfusions.

quoteProf Fabian Müller
Confidence
1.00
02

For the past 14 months she has been in treatment-free remission and largely able to return to normal life.

factual
Confidence
0.90
03

Within weeks of having the cell therapy, doctors noticed that all three diseases had responded.

factual
Confidence
0.90
04

A woman with three life-threatening autoimmune diseases returned to a near-normal life after cell therapy.

factual
Confidence
0.90
05

Clinical trials were needed to learn how durable the therapy was and whether it would be effective for other autoimmune diseases.

quoteProf Fabian Müller
Confidence
0.80
§ 04

Full report

3 min read · 563 words
A woman who lived with three life-threatening autoimmune diseases for more than a decade has returned to a near-normal life after a cell therapy reset her wayward immune system.The 47-year-old had had nine different treatments, none of which had a lasting impact, before receiving the therapy last year at University Hospital Erlangen in Germany. At the time, she required daily blood transfusions and permanent blood thinning medication to control her illness.Within weeks of having the cell therapy, doctors noticed that all three diseases had responded, marking a world first and a striking improvement in the woman’s condition. For the past 14 months she has been in treatment-free remission and largely able to return to normal life.Prof Fabian Müller, who led the team, said the speed and depth of the woman’s response was “remarkable” and the therapy had “significantly improved her quality of life”. Clinical trials were needed to learn how durable the therapy was and whether it would be effective for other autoimmune diseases, he said.The woman had a rare, life-threatening blood disorder, autoimmune haemolytic anaemia (AIHA), whereby rogue immune defences destroy red blood cells. In flare-ups, patients need immunosuppressant drugs and regular blood transfusions. In the woman’s case, standard treatments were no longer working. “The patient had no treatment options left and would not have left the ward as she needed daily transfusions,” Müller said.In addition to AIHA, the woman had two other autoimmune diseases. One, immune thrombocytopenia (ITP), is driven by immune cells destroying platelets, which raises the risk of bleeding. The other, known as antiphospholipid syndrome (APS), has an opposing effect and raises the risk of harmful blood clots. All three diseases were due to wayward B-cells which make infection-fighting antibodies.With no options left, the doctors offered a treatment known as CAR (chimeric antigen receptor) T-cell therapy, which has proved gamechanging for certain cancers. The team extracted the woman’s white blood cells and isolated her T-cells, which patrol the body and kill infected or abnormal cells. The doctors engineered the T-cells to recognise a protein called CD19 found on B-cells and re-infused them into the patient.The therapy swiftly went to work, destroying the rogue B-cells. The woman had her last blood transfusion a week after the treatment and was strong enough for everyday activities two weeks later. Her immune system appeared to have stopped attacking her red blood cells, and her other autoimmune conditions improved. When her B-cells bounced back months later, they appeared to be healthy, suggesting the therapy reset her immune system. Details are published in the journal Med.The woman still has a low white blood cell count and slightly raised liver enzymes, but the researchers believe these are due to years of previous treatments rather than the CAR-T therapy.Prof Ben Parker, a consultant rheumatologist at the Kellgren Centre for Rheumatology at Manchester University NHS foundation trust, said it was encouraging that all the patient’s conditions seemed to respond to the therapy. “The prolonged response off normal therapy suggests there has been an immune reset,” he said, though how long it would last remained unclear.Parker, who is leading CAR-T trials on lupus and related autoimmune conditions in Manchester, said: “There are many active trials currently recruiting across autoimmune conditions, including lupus, myositis, MS, systemic sclerosis, vasculitis, and some have already reported early results. Case reports don’t prove a treatment works for wider use, hence the need for trials.”
§ 05

Entities

4 identified
Key playerOppositionContextPositiveNeutralNegative
§ 06

Keywords & salience

9 terms
cell therapy
1.00
autoimmune diseases
0.90
treatment-free remission
0.70
car t-cell therapy
0.70
immune system
0.60
autoimmune haemolytic anaemia (aiha)
0.50
blood transfusions
0.50
immune thrombocytopenia (itp)
0.40
antiphospholipid syndrome (aps)
0.40
§ 07

Topic connections

Interactive graph